NCT06223516 - Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Multiple Myeloma

Interventions

DRUG

Subcutaneous (SC) ABBV-383

SC Injection

DRUG

Intravenous (IV) ABBV-383

IV Infusion

Trial Locations (15)

20246

RECRUITING

Universitaetsklinikum Hamburg-Eppendorf /ID# 260444, Hamburg

27157

RECRUITING

Atrium Health Wake Forest Baptist Medical Center /ID# 260807, Winston-Salem

32224

RECRUITING

Mayo Clinic /ID# 262808, Jacksonville

48109

RECRUITING

University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 261050, Ann Arbor

50937

RECRUITING

Universitaetsklinikum Koeln /ID# 260445, Cologne

53226

COMPLETED

Wisconsin Medical Center /ID# 261085, Milwaukee

60590

RECRUITING

Universitaetsklinikum Frankfurt /ID# 260442, Frankfurt am Main

85054

RECRUITING

Mayo Clinic Arizona /ID# 260799, Phoenix

91120

RECRUITING

Hadassah Medical Center-Hebrew University /ID# 261446, Jerusalem

5265601

RECRUITING

The Chaim Sheba Medical Center /ID# 261699, Ramat Gan

6423906

RECRUITING

Tel Aviv Sourasky Medical Center /ID# 261525, Tel Aviv

33136-1002

RECRUITING

Sylvester Comprehensive Cancer Center /ID# 260798, Miami

55905-0001

RECRUITING

Mayo Clinic - Rochester /ID# 262807, Rochester

466-8650

RECRUITING

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 265286, Nagoya

589-8511

RECRUITING

Kindai University Hospital /ID# 266016, Osaka Sayama-shi